Beranda › Sarkoma Ewing › Florida
Uji klinis Sarkoma Ewing di Florida
7 studi untuk Sarkoma Ewing mencari peserta di lokasi di Florida.
Kota di Florida
Teks studi resmi (Bahasa Inggris)
Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes
- University of Florida, Gainesville
- Nemours Jacksonville, Jacksonville
- University of Miami, Miami
- dan 2 lainnya
Menerima pesertaFase 1
Usia 1 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07194044Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Johns Hopkins All Children's Hospital ( Site 1025), St. Petersburg
Menerima pesertaFase 1/2
6 Months – 25 Years · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT06395103Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
- University of Florida, Gainesville
- Nicklaus Children's Hospital, Miami
- Arnold Palmer Hospital for Children, Orlando
- dan 1 lainnya
Menerima pesertaFase 1/2
Hingga usia 26 · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06465199Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
- University of Florida, Gainesville
- Nicklaus Children's Hospital, Miami
- Arnold Palmer Hospital for Children, Orlando
- dan 2 lainnya
Menerima pesertaFase 1/2
Hingga usia 30 · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06541262Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma
- St. Joseph's Children's Hospital, Tampa
Menerima pesertaFase 2
Usia 0 hingga 50 · Semua jenis kelamin · Diperbarui 9 Jul 2026 · NCT07321912Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
- University of Florida, Gainesville
Menerima pesertaFase 1/2
6 Months – 25 Years · Semua jenis kelamin · Diperbarui 30 Jun 2026 · NCT06625190Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
- Johns Hopkins All Children's Hospital, St. Petersburg
Menerima pesertaFase 1/2
Usia 2 hingga 30 · Semua jenis kelamin · Diperbarui 3 Feb 2026 · NCT05734066Dari ClinicalTrials.gov, data diambil 2 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.